First Teaching Hospital, Tianjin University of Traditional Chinese Medicine
天津中医药大学第一附属医院
Listed for 5 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at First Teaching Hospital, Tianjin University of Traditional Chinese Medicine
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Lung cancer肺癌26 papers led4 open trials led
- Breast cancer乳腺癌5 papers led4 open trials led
- Multiple myeloma多发性骨髓瘤3 papers led
- Coronary heart disease冠心病6 papers led
- IgA nephropathyIgA 肾病1 paper led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Lung cancer
肺癌Led 26 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.1%.
- Open trials as a site
- 0
- led by another institution
7 hospitals in Tianjin for lung cancer251 hospitals in China for lung cancer
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingElectroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07034326
Age 18 years to 80 years (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- RecruitingElectroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT07086300
Age 65 years to 100 years (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- RecruitingElectroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
- Phase
- N/A
- Started
- 2025-11
- Posted
- Registry
- NCT07239661
Age 18 years to Not stated (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- RecruitingEffect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer
- Phase
- N/A
- Started
- 2024-04
- Posted
- Registry
- NCT06548711
Age 18 years to 80 years (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led26
- From autoimmune inflammation to malignancy: causal genetic evidence for the RA-squamous cell lung cancer axis.
- Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer.
- Association between advanced lung cancer inflammation index and cognitive function among US older adults from a cross-sectional survey of the NHANES 2011 to 2014.
- Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets.
- Treatment Advances in Lung Cancer with Leptomeningeal Metastasis.
- Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review.
- Immunosenescence and immunotherapy in older NSCLC patients.
- Study of the mechanism by which Xiaoyan decoction combined with E7449 regulates tumorigenesis in lung adenocarcinoma.
- Identification and analysis of prognostic immune cell homeostasis characteristics in lung adenocarcinoma.
- Immune checkpoint inhibitors for RET fusion non-small cell lung cancer: hopes and challenges.
- Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer.
- Advances in immune checkpoint inhibitors therapy for small cell lung cancer.
- The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer.
- A clinical nomogram based on absolute count of lymphocyte subsets for predicting overall survival in patients with non-small cell lung cancer.
- Combination Treatment with Iodine 125 Seeds Implant and Systemic Therapy vs. Systemic Therapy Alone for Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.
- A novel long noncoding RNA (lncRNA), LINC02657(LASTR), is a prognostic biomarker associated with immune infiltrates of lung adenocarcinoma based on unsupervised cluster analysis.
- RGN as a prognostic biomarker with immune infiltration and ceRNA in lung squamous cell carcinoma.
- Autophagy and Glycometabolic Reprograming in the Malignant Progression of Lung Cancer: A Review.
- Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
- ADAMTS8 inhibited lung cancer progression through suppressing VEGFA.
- Clinical predictive value of naïve and memory T cells in advanced NSCLC.
- Evodiamine suppresses the progression of non-small cell lung carcinoma via endoplasmic reticulum stress-mediated apoptosis pathway in vivo and in vitro.
- A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma.
- The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
- Lentinan combined with cisplatin for the treatment of non-small cell lung cancer.
- Is COVID-19 a high risk factor for lung cancer?: A protocol for systematic review and meta-analysis.
Chinese-language papers (not in the count)3
All its trials on ClinicalTrials.gov, any status4
- Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
- Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
- Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
- Effect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer
Cancer
Breast cancer
乳腺癌Led 5 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.03%.
- Open trials as a site
- 0
- led by another institution
4 hospitals in Tianjin for breast cancer219 hospitals in China for breast cancer
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingElectroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07490938
Age 18 years to 75 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesTianjin, Wuhan, Xining
- RecruitingAnalysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07763587
Age 18 years to 70 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 1 listed hospital as study siteTianjin
- Not yet recruitingEffect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07481903
Age 18 years to 75 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesBeijing, Nanjing, Tianjin
- Not yet recruitingStudy on the Construction and Implementation Effect of a Traditional Chinese Medicine-Based Mental-Physical Comorbidity Linked Health-Management System of "Hospital-Community-Family" for Breast Cancer Patients
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07942103
Age 18 years to 70 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led5
- Breast cancer-targeted therapy and doxorubicin multidrug resistance are reversed via macrophage membrane-camouflaged liposomes.
- Expression of G-quadruplex coordinates BRCA1, CDH1, and RASSF1 via DNA methylation in mouse breast cancer cells.
- HER3 receptor and its role in the therapeutic management of metastatic breast cancer.
- Effects of Acupuncture on Breast Cancer Patients Taking Aromatase Inhibitors.
- The Predictive Value of Changes in the Absolute Counts of Peripheral Lymphocyte Subsets for Progression and Prognosis in Breast Cancer Patients.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status4
- Study on the Construction and Implementation Effect of a Traditional Chinese Medicine-Based Mental-Physical Comorbidity Linked Health-Management System of "Hospital-Community-Family" for Breast Cancer Patients
- Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen
- Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors
- Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Tianjin for multiple myeloma175 hospitals in China for multiple myeloma
No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led3
- MiR-503-5p as a potential biomarker for deep venous thrombosis (DVT) in multiple myeloma (MM) and its role in disease development.
- Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease.
- Severe lung injury induced by CD38 monoclonal antibody Daratumumab and bortezomib-containing regimen in a patient with preexisting interstitial lung disease: a case report and literature review.
Other diseases
Coronary heart disease
冠心病Led 6 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.1%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Tianjin for coronary heart disease231 hospitals in China for coronary heart disease
No open trial on coronary heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led6
- Cardiac lymphatic system and coronary heart disease: associations, mechanisms and therapeutic strategies.
- Neuro-immune interactions in coronary microvascular disease: mechanisms and therapeutic prospect.
- Qishen Yiqi Dripping Pills for Cardiovascular Diseases: Effects and Mechanisms.
- Effects of empowerment education on patients after percutaneous coronary intervention: A meta-analysis and systematic review.
- From Iron Metabolism to Ferroptosis: Pathologic Changes in Coronary Heart Disease.
- Protocol to study the effects of Traditional Chinese Medicine on patients with coronary heart disease showing phlegm-heat-stasis symptom pattern.
Chinese-language papers (not in the count)1
Other diseases
IgA nephropathy
IgA 肾病Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Tianjin for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Getting in touch
Name card to show staff or a driver
天津中医药大学第一附属医院
First Teaching Hospital, Tianjin University of Traditional Chinese Medicine
天津
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; 中国传统医药的天津大学第一附属医院